| Literature DB >> 25691612 |
Jaffer A Ajani, Thomas A D'Amico, Khaldoun Almhanna, David J Bentrem, Stephen Besh, Joseph Chao, Prajnan Das, Crystal Denlinger, Paul Fanta, Charles S Fuchs, Hans Gerdes, Robert E Glasgow, James A Hayman, Steven Hochwald, Wayne L Hofstetter, David H Ilson, Dawn Jaroszewski, Kory Jasperson, Rajesh N Keswani, Lawrence R Kleinberg, W Michael Korn, Stephen Leong, A Craig Lockhart, Mary F Mulcahy, Mark B Orringer, James A Posey, George A Poultsides, Aaron R Sasson, Walter J Scott, Vivian E Strong, Thomas K Varghese, Mary Kay Washington, Christopher G Willett, Cameron D Wright, Debra Zelman, Nicole McMillian, Hema Sundar.
Abstract
Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. Targeted therapies with trastuzumab and ramucirumab have produced encouraging results in the treatment of advanced or metastatic EGJ adenocarcinomas. Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus and EGJ.Entities:
Mesh：
Year: 2015 PMID： 25691612 DOI： 10.6004/jnccn.2015.0028
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908